Is RMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.

RMD (ResMed Inc.) Stock Analysis - Financials

ResMed Inc. (RMD) is a publicly traded Healthcare sector company. As of July 8, 2026, RMD trades at $207.39 with a market cap of $31.68B and a P/E ratio of 20.95. RMD moved -5.41% today. Year to date, RMD is -9.60%; over the trailing twelve months it is -14.30%. Its 52-week range spans $180.27 to $293.81. Analyst consensus is buy with an average price target of $256.09. Rallies surfaces RMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are RMD's key financials?

RMD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RMD recently traded at $207.39. Market cap is $31.68B. P/E ratio is 20.95. Revenue is $5.54B.

RMD Key Metrics

Key financial metrics for RMD
Metric	Value
Price	$207.39
Market Cap	$31.68B
P/E Ratio	20.95
EPS	$10.41
Dividend Yield	0.60%
52-Week High	$293.81
52-Week Low	$180.27
Volume	865.12K
Avg Volume	0
Revenue (TTM)	$5.54B
Net Income	$1.52B
Gross Margin	61.59%

RMD Analyst Consensus

14 analysts cover RMD: 0 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $256.09.

Common questions about RMD

What are RMD's key financials?: RMD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RMD recently traded at $207.39. Market cap is $31.68B. P/E ratio is 20.95. Revenue is $5.54B.
Is RMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.